This has to do with SequestOx not getting approved and the company having zero additional revenue streams approved since then and continuing to dilute. This has to do with the OTC - not that management has done anything wrong here. I understand the situation the company is highly undervalued at this point on generics alone. I could care less what other investors think about all of this. I continue to buy on the dips.
News 
Market Data 
Discover 
